BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Inc Earnings'. (Return)

MarketWatch MarketPulseAug 04, 2020
WW stock falls more than 7% after company's Q2 earnings miss
WW International Inc. shares fell more than 7% in the extended session Tuesday after the company formerly known as Weight Watchers reported second-quarter adjusted profit and sales below Wall Street expectations. WW said it earned $14 million, or 20 cents a share, in the quarter, compared with earnings of $54 million, or 78 cents a share, in the year-ago period. Adjusted for one-time items, the company earned 67 cents a share. Sales fell to $334 million from $369 million a year ago. Analysts polled by FactSet had expected adjusted earnings of 70 cents a share on sales of $339 million. WW said it ended the quarter with its highest-ever second-quarter subscriber base of 5 million people, "driven by a record level of digital subscribers." Location closures due to COVID-19, however, dented service and product sales, the company said. "We are nimbly managing our studio cost structure and are on-track to deliver on our $100 million cost-savings initiative, while maintaining strong liquidity and financial flexibility," Chief Financial Officer Nick Hotchkin said in a statement.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



The Motley FoolAug 04, 2020
CatchMark Timber Trust Inc (CTT) Q2 2020 Earnings Call Transcript
CTT earnings call for the period ending June 30, 2020.

RELATED ARTICLES
Green Plains Inc (GPRE) Q2 2020 Earnings Call Transcript (The Motley Fool)

MarketWatch MarketPulseAug 04, 2020
Stocks close higher as stimulus talks continue, with Nasdaq notching new high
Stocks closed modestly higher after a choppy trading session Tuesday, with investors keeping one eye on stimulus talks in Washington and another on mixed corporate earnings. The Dow Jones Industrial Average gained about 166 points to close 0.6% higher, near 26,830, while the S&P 500 closed at 3,307, according to preliminary estimates, up 12 points or 0.4%. The tech-heavy Nasdaq started off the day strong, slipped into the red, and rebounded late in the session to close 0.4%, 38 points, higher, near 10,941, another record close. Shares of Abiomed Inc. lost ground even after the company said its Impella heart pump had received an emergency use authorization from the FDA for use as a treatment for some COVID-19 patients. On Capitol Hill, a stimulus deal for the coronavirus-battered economy did not appear imminent.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



The Motley FoolAug 04, 2020
JELD-WEN Holding, Inc. (JELD) Q2 2020 Earnings Call Transcript
JELD earnings call for the period ending June 30, 2020.

Yahoo BusinessAug 04, 2020
3 "Strong Buy" Penny Stocks That Could Go Boom
The stock market has been holding up remarkably well, but why? Against the backdrop of weak second quarter earnings results, investors are piling in on the hope that a COVID-19 vaccine is coming, there will be additional stimulus and corporate profits will bounce back.Morgan Stanley's chief U.S. equity strategist Mike Wilson believes the U.S. is experiencing a V-shaped recovery, noting that the current state of the market resembles other recessionary periods right before economic expansion took place. He argues that given the possibility of a "tremendous" rise in operating leverage post-pandemic, the increased efficiency will translate to higher profits.Taking this outlook into consideration, we set out to find exciting opportunities that won't break the bank, namely penny stocks. As these tickers trading for less than $5 per share carry risk, due diligence is essential. Using TipRanks' database, we locked in on three that have garnered glowing reviews from the Street, enough to earn a "Strong Buy" consensus rating. Not to mention each offers massive upside potential.Aileron Therapeutics (ALRN)Focused on improving chemotherapy, Aileron Therapeutics wants to help cancer patients fight the disease without the fear or burden of chemotherapy-induced side effects. Based on its recent encouraging data readout and $0.90 share price, this healthcare name has landed right under Wall Street's microscope.On June 1, ALRN announced positive interim results from the ongoing ALRN-6924 myelopreservation trial in patients with small-cell lung cancer (SCLC) being
TRENDING TAGS
Coronaviruscases latest live pandemic rise
StockMarket record Today Nasdaq Kodak
earningsCall Transcript Q2 Inc Disney
pandemicduring coronavirus How Amid Disney
COVID-19States Due amid during Lost
Disneyearnings theme park billion pandemic
TikTokMicrosoft Trump Deal China ByteDance
StocksNasdaq record high making biggest
ChinaTikTok Lawsuit About Microsoft Class
IncCall Earnings Transcript Filer Q2

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC